🏢 官网IRSRRKCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:15:00时区推断·⟳ 抓取 04:17:48回填·⚡ 决策 07-18 04:18:59·101.6 天前
Scholar Rock披露向新员工授予纳斯达克规则下的入职激励股权
公司仅披露向11名新员工授予合计118586股相关期权和RSU，属于美股生物科技公司常规员工激励事项。
📄 原文SRRK↗ 原文
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Skip to main navigation Skip to primary navigation Skip to main content Skip to primary sidebar Skip to footer Scholar…
不做 Scholar Rock（SRRK.US）
常规新员工股权激励披露，不改变管线、监管、收入或融资预期，无法形成可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-17 · 扩散 low · price-in 风险 low ↗
关键理由
- 公司仅披露向11名新员工授予合计118586股相关期权和RSU，属于美股生物科技公司常规员工激励事项。
- 该事项不改变apitegromab管线进展、监管里程碑、商业化预期、现金流或融资条件，无法形成短周期同向交易催化。
主要风险
- 若后续另有临床、FDA、融资或商业化进展，应作为新事件重新评估。
原文全文
展开原文 · 5,936 字
Skip to main navigation
Skip to primary navigation
Skip to main content
Skip to primary sidebar
Skip to footer
Scholar Rock, Inc.
Careers
Newsroom
Contact Us
Learn about our commitment to creating possibilities for those living with serious disease.
Patients & Families
Our Company
Meet Scholar Rock, a biopharmaceutical company committed to improving lives.
Our Company
Our Science
Discover how our breakthrough approach treats complex disease at its biological root.
Our Science
Our Pipeline
Investors & Media
Investors & Media
Press Releases
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investors and Media
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Main content section
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
PDF Version
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 17, 2026--
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 118,586 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 33,987 shares of common stock and inducement restricted stock units, covering an aggregate of 84,599 shares of its common stock.
The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.
The Plan, initially adopted by the Company’s board of directors on June 16, 2022 , and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock , or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock , pursuant to Nasdaq Listing Rule 5635(c)(4).
The inducement stock options have an exercise price of $54.70 , which is equal to the closing price of Scholar Rock’s common stock on July 13, 2026 . The inducement stock options will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of each employee’s start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 12 equal quarterly installments thereafter. Vesting for the inducement restricted stock units will be in four equal annual installments. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.
About Scholar Rock
Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.
Scholar Rock ® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com , including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260717998564/en/
Scholar Rock:
Investors
Laura Ekas, Ph.D.
917-439-0374
ir@scholarrock.com
Media
Jeff Smith
682-401-8428
Molly MacLeod, Ph.D.
802-579-5995
media@scholarrock.com
Source: Scholar Rock
Footer
Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142
Phone: 857.259.3860
info@scholarrock.com
© 2026 All Rights Reserved
We are Scholar Rock.
A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.
Learn More About Our Pipeline
Patients & Families
Areas of Focus
Spinal Muscular Atrophy
Patient Stories
Clinical Trials
Resources
Expanded Access
Our Company
Our Company
Mission & Vision
Newsroom
Careers
Management Team
Board of Directors
Our Science
Our Science
Platform
Publications & Posters
Our Pipeline
Neuromuscular and Obesity
Spinal Muscular Atrophy
Immuno-Oncology
Cancer (solid tumors)
Fibrotic Diseases
Hematology
Anemia
Investors & Media
Press Releases
Archived Press Releases
Events & Presentations
Corporate Governance
Management Team
Board of Directors
Committee Composition
Financials & Filings
SEC Filings
Stock Information
Historical Stock Lookup
Investment Calculator
Analyst Coverage
Investor FAQs
Contact IR or Media
Careers
Newsroom
Contact Us
Skip to primary navigation
Skip to main content
Skip to primary sidebar
Skip to footer
Scholar Rock, Inc.
Careers
Newsroom
Contact Us
Learn about our commitment to creating possibilities for those living with serious disease.
Patients & Families
Our Company
Meet Scholar Rock, a biopharmaceutical company committed to improving lives.
Our Company
Our Science
Discover how our breakthrough approach treats complex disease at its biological root.
Our Science
Our Pipeline
Investors & Media
Investors & Media
Press Releases
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investors and Media
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Main content section
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
PDF Version
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 17, 2026--
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 118,586 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 33,987 shares of common stock and inducement restricted stock units, covering an aggregate of 84,599 shares of its common stock.
The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.
The Plan, initially adopted by the Company’s board of directors on June 16, 2022 , and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock , or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock , pursuant to Nasdaq Listing Rule 5635(c)(4).
The inducement stock options have an exercise price of $54.70 , which is equal to the closing price of Scholar Rock’s common stock on July 13, 2026 . The inducement stock options will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of each employee’s start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 12 equal quarterly installments thereafter. Vesting for the inducement restricted stock units will be in four equal annual installments. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.
About Scholar Rock
Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.
Scholar Rock ® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com , including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260717998564/en/
Scholar Rock:
Investors
Laura Ekas, Ph.D.
917-439-0374
ir@scholarrock.com
Media
Jeff Smith
682-401-8428
Molly MacLeod, Ph.D.
802-579-5995
media@scholarrock.com
Source: Scholar Rock
Footer
Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142
Phone: 857.259.3860
info@scholarrock.com
© 2026 All Rights Reserved
We are Scholar Rock.
A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.
Learn More About Our Pipeline
Patients & Families
Areas of Focus
Spinal Muscular Atrophy
Patient Stories
Clinical Trials
Resources
Expanded Access
Our Company
Our Company
Mission & Vision
Newsroom
Careers
Management Team
Board of Directors
Our Science
Our Science
Platform
Publications & Posters
Our Pipeline
Neuromuscular and Obesity
Spinal Muscular Atrophy
Immuno-Oncology
Cancer (solid tumors)
Fibrotic Diseases
Hematology
Anemia
Investors & Media
Press Releases
Archived Press Releases
Events & Presentations
Corporate Governance
Management Team
Board of Directors
Committee Composition
Financials & Filings
SEC Filings
Stock Information
Historical Stock Lookup
Investment Calculator
Analyst Coverage
Investor FAQs
Contact IR or Media
Careers
Newsroom
Contact Us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。